224 related articles for article (PubMed ID: 15118933)
1. Immune implications of gene therapy for hemophilia.
Herzog RW; Dobrzynski E
Semin Thromb Hemost; 2004 Apr; 30(2):215-26. PubMed ID: 15118933
[TBL] [Abstract][Full Text] [Related]
2. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
Couto LB
Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
[TBL] [Abstract][Full Text] [Related]
3. Nonviral gene therapy approaches to hemophilia.
Gómez-Vargas A; Hortelano G
Semin Thromb Hemost; 2004 Apr; 30(2):197-204. PubMed ID: 15118931
[TBL] [Abstract][Full Text] [Related]
4. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Van Damme A; Chuah MK; Collen D; VandenDriessche T
Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns.
Lillicrap D
Haematologica; 2000 Oct; 85(10 Suppl):108-11; discussion 111-2. PubMed ID: 11187861
[TBL] [Abstract][Full Text] [Related]
6. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
7. Preclinical animal models for hemophilia gene therapy: predictive value and limitations.
Rawle FE; Lillicrap D
Semin Thromb Hemost; 2004 Apr; 30(2):205-13. PubMed ID: 15118932
[TBL] [Abstract][Full Text] [Related]
8. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
[TBL] [Abstract][Full Text] [Related]
9. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
10. Preclinical gene therapy studies for hemophilia using adenoviral vectors.
Thorrez L; VandenDriessche T; Collen D; Chuah MK
Semin Thromb Hemost; 2004 Apr; 30(2):173-83. PubMed ID: 15118929
[TBL] [Abstract][Full Text] [Related]
11. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
DiMichele D; Kroner B;
Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for hemophilia.
Ponder KP
Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
[TBL] [Abstract][Full Text] [Related]
13. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
Iizuka A
Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
[No Abstract] [Full Text] [Related]
14. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
15. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
16. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
[TBL] [Abstract][Full Text] [Related]
17. International workshop on immune tolerance induction: consensus recommendations.
DiMichele DM; Hoots WK; Pipe SW; Rivard GE; Santagostino E
Haemophilia; 2007 Jul; 13 Suppl 1():1-22. PubMed ID: 17593277
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
Rup B
Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for hemophilia A.
Gan SU; Calne RY
Discov Med; 2006 Oct; 6(35):198-202. PubMed ID: 17234142
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for hemophilia "A" and "B": efficacy, safety and immune consequences.
Chuah M; Vandendriessche T
Verh K Acad Geneeskd Belg; 2007; 69(5-6):315-34. PubMed ID: 18351211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
